Controlling embryonic stem cell proliferation and pluripotency: the role of PI3K-and GSK-3-dependent signalling by Welham, Melanie J et al.
        
Citation for published version:
Welham, MJ, Kingham, E, Sanchez Ripoll, Y, Kumpfmueller, B, Storm, M & Bone, H 2011, 'Controlling
embryonic stem cell proliferation and pluripotency: the role of PI3K-and GSK-3-dependent signalling',








The final version of record is available at http://www.biochemsoctrans.org/bst/
University of Bath
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 23. Jan. 2020
  1 
 
Controlling embryonic stem cell proliferation and pluripotency: the role of 
phosphoinositide 3-kinase- and glycogen synthase kinase-3-dependent signaling 
 
Melanie J Welham1,*, Emmajayne Kingham1,2, Yolanda Sanchez-Ripoll1, Benjamin 
Kumpfmueller1, Michael Storm1 and Heather Bone1 
 
1Centre for Regenerative Medicine,  
Department of Pharmacy & Pharmacology,  
University of Bath,  
Bath, BA2 7AY, UK 
 
2Present Address: Bone and Joint Research Group, Centre for Human Development, Stem Cells 
and Regeneration, Developmental Origins of Health and Disease, Institute of Developmental 
Sciences, University of Southampton, Southampton, SO16 6YD. 
 
 
* Corresponding author 
Tel: +44 1225 386428 
Fax: +44 1225 386114 
Email: prsmjw@bath.ac.uk 
 
2565 words including Acknowledgements and Figure legends 
2 Black & White Figures 
48 references  
 
Abbreviations: ERas, ES cell-expressed Ras; ERK, extracellular regulated kinase; ESC, 
embryonic stem cell; GSK-3, glycogen synthase kinase-3; LIF, leukaemia inhibitor factor; MEK, 
MAP and ERK kinase; mTOR mammalian target of rapamycin; PI, phosphoinositide; PI3K, 
phosphoinositide 3-kinase; PTEN, phosphatase and tenscin homologue deleted on chromosome 
10; Stat3, signal transducer and activator of transcription 3 
 






Embryonic stem cells (ESCs) are derived from the inner cell mass of preimplantation embryos 
and are pluripotent, meaning they can differentiate into all cells that make up the adult organism. 
This property of pluripotency makes ESCs attractive as a model system for studying early 
development and for the generation of specific cell types for use in regenerative medicine and 
drug screening. In order to harness their potential, the molecular mechanisms regulating ESC 
pluripotency, proliferation and differentiation (i.e. cell fate) need to be understood such that 
pluripotency can be maintained during expansion, while differentiation to specific lineages can be 
induced accurately when required. This review will focus on the potential roles that 
phosphoinositide 3-kinase (PI3K) and glycogen synthase kinase 3 (GSK-3)-dependent signaling 
play in coordination and integration of mouse ESC pluripotency and proliferation and contrast this 
with our understanding of their functions in human ESCs. 
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Control of embryonic stem cell fate: an overview 
Embryonic stem cells are derived from early pre-implantation embryos and when cultured 
appropriately can be maintained in a proliferative, self-renewing, pluripotent state almost 
indefinitely. Pluripotency is the ability to differentiate into all cells found in an adult organism, 
while self-renewal describes the generation of a daughter stem cell from its mother. In the case of 
ESCs, self-renewal occurs symmetrically, such that when an undifferentiated ESC divides and 
pluripotency is maintained, both its progeny will be undifferentiated [1]. Thus, although not 
commonly described as such, self-renewal of ESCs requires simultaneous control of both the cell 
cycle (proliferation) and maintenance of pluripotency. It is important to emphasize that self-
renewal is NOT the same as proliferation [2, 3] because the latter can occur when pluripotency is 
not maintained.  
 
Over the past 5-10 years our understanding of the molecular components involved in maintaining 
pluripotency of mouse ESCs has increased dramatically, from a simple ‘prelude’ where Signal 
transducer and activator of transcription (Stat3) activation by Leukaemia inhibitor factor (LIF) was 
all that seemed necessary, to a complex ‘symphony’ where extrinsic factors, intracellular signals, 
transcription factors, epigenetic regulators and microRNAs have all been implicated [4]. Three 
transcription factors, Oct4, Sox2 and Nanog, are considered the 'master' regulators of ESC 
pluripotency and were initially proposed to form a self-sustaining gene regulatory network 
(reviewed in [5]). However, revision of this model is now necessary to accommodate recent 
findings, namely that ESC populations are not homogeneous [6, 7] and indeed, within populations 
of ESCs, expression of Nanog [8] Essrb [9] and Rex1 [10] have all been shown to be both 
heterogeneous and dynamic. Despite our progress in understanding the factors that influence 
pluripotency there remains a significant gap in our knowledge regarding the molecular 
mechanisms responsible for the coordination and integration of ESC proliferation and 
pluripotency [2, 3].  
 
The ESC cell cycle 
Mouse ESCs proliferate rapidly in culture and display unique cell cycle kinetics, distinct from 
those of somatic cells, dividing approximately every 11-16h and exhibiting a shortened G1 phase 
[11, 12]. Throughout the mouse ESC cell cycle it has been reported that cyclin levels remain 
relatively stable [12],  cyclinA/E:cyclin-dependent kinase 2 (Cdk2) complexes are active and the 
Retinoblastoma protein remains hyperphosphorylated [11, 12]. In addition, cell cycle progression 
appears to be insensitive to inhibition by p16INK4a [13] and neither do mouse ESCs arrest following 
DNA damage [14]. By contrast, it has been reported that levels of cyclins D1, D2 and D3 do vary 
throughout the cell cycle of human ESCs and knock-down of CDK2 leads to G1 arrest and 
differentiation to extraembryonic lineages [15]. Recently, in human ESCs pluripotency regulators 
  4 
have been linked directly with control of the cell cycle. It has been demonstrated that mir302 
miRNAs are regulated by OCT3/4 and SOX2, that mir302a targets cell cycle regulators and that 
inhibition of mir302a results in increased cyclin D1 levels and increased numbers of hESCs in G1 
[16]. In mouse ESCs it has been reported that the mir290 cluster of miRNAs regulate G1/S-phase 
transition by controlling levels of p21Cip and p27Kip1 and are important for promoting rapid 
proliferation [17]. These results are somewhat at odds with earlier studies that had suggested 
little role for these cyclin-dependent kinase inhibitors in the control of the mouse ESC cell cycle. 
Thus, while control of the cell cycle may vary between mouse and human ESCs, a number of 
important questions relating to this regulation remain unanswered. 
 
Phosphoinositide 3-Kinase (PI3K) signaling and ESC biology 
PI3Ks are a family of lipid kinases, comprising 3 sub-classes [18, 19]. Class IA PI3Ks are 
heterodimers comprising a regulatory subunit (3 genes, 5 isoforms, p85α, p55α, p50α, p85β  & 
p55γ) and a catalytic subunit (3 genes and 3 isoforms: p110α, β and δ). The primary product of 
class I PI3K activity is the phosphoinositide PI(3,4,5)P3 which recruits pleckstrin homology 
domain-containing proteins to the plasma membrane, facilitating activation of a range of 
downstream signalling cascades [20]. Functionally, PI3Ks have been implicated in a wide array of 
physiological processes including proliferation, development, growth and migration [20]. Of 
particular interest in relation to ESCs is the report that ablation of p110β leads to lethality at the 
pre-implantation stage, suggesting a key role for PI3Ks during early mouse embryogenesis [21]. 
Studies conducted over the past few years have suggested roles for PI3Ks in both control of ESC 
cell cycle, proliferation and also in maintenance of pluripotency.  
 
Involvement of PI3Ks in control of ESC proliferation The first suggestion that PI3Ks were 
involved in control of ESC proliferation came from the observation that mouse ESCs lacking the 
PTEN tumour suppressor gene (a negative regulator of PI3K signaling) exhibited enhanced 
proliferation and diminished dependence on serum [22]. Subsequently, incubation of murine 
ESCs with high doses of the broad selectivity PI3K inhibitor, LY294002, decreased proliferation 
and led to cells accumulating in G1 [23]. Eras, a constitutively active member of the Ras family of 
small GTPases, is expressed specifically in mouse ESCs and its deletion also leads to decreased 
proliferation [24]. Interestingly, this proliferative defect could be rescued by over-expression of a 
membrane bound form of the catalytic PI3K subunit p110α, providing a further link between 
PI3Ks and mESC proliferation [24]. Additional evidence to support a role for PI3K signaling in 
ESC proliferation comes from the finding that deletion of mammalian target of rapamycin 
(mTOR), a downstream target of the PI3K signaling pathway, leads to an early embryonic 
lethality in mice and an inability of mTOR null mESCs to proliferate; similar results are observed 
  5 
upon inhibition of mTOR with Rapamycin [25]. Despite these reports, the molecular mechanisms 
that underpin the involvement of PI3Ks in regulation of ESC proliferation are unresolved. One 
possibility it that PI3K-dependent signals contribute to promoting the constitutive activity of 
cyclinE:Cdk2 complexes in mESCs. In somatic cells PI3K signalling inhibits the activity of the 
transcription factor FOXO3. In ESCs this could limit expression of p27Kip1 meaning cyclinE:cdk2 
activity would be largely unchecked. In addition, PI3K-mediated inhibition of GSK-3 activity would 
prevent the phosphorylation-dependent ubiquitination and degradation of cyclinE, which again 
could contribute to the maintenance of high constitutive levels of cyclinE:cdk2 complexes that 
play a role in driving ESC proliferation.  
 
PI3Ks and regulation of mESC fate Our work, alongside that of others, has also implicated 
PI3K-dependent signaling in control of mouse ESC self-renewal. We were the first to suggest a 
role for PI3K signaling in maintenance of mESC pluripotency, demonstrating that doses of 
LY294002 close to its IC50 value of 5 µM reduced the ability of murine ESCs to retain 
pluripotency [26]. Other groups have demonstrated that an activated form of Akt, one of the key 
downstream targets of PI3K signaling, promotes self-renewal independently of LIF [27]. Akt was 
also identified in an RNAi screen as a regulator of mESC pluripotency [28]. Relatively few studies 
have examined the role of PI3Ks in the regulation of human ESC fate. PI3K signaling has been 
implicated in neurotrophin-mediated survival of hESCs [29] as well as maintenance of 
pluripotency [30], although these studies were limited to the use of LY294002.  
 
We have recently identified genes regulated by PI3K-dependent signaling in murine ESCs, 
among which are a number of known regulators of pluripotency including Nanog, Klf4, Tbx3, Tcl1 
and Esrrb [31, 32]. It has subsequently been suggested that PI3K signaling controls Nanog 
expression via effects on Tbx3 [33], results entirely consistent with our own observations. Our 
transcriptome analyses also revealed potential novel regulators of pluripotency including the 
tyrosine phosphatase Shp1 and members of Zscan4 family of Zinc finger proteins [32]. We 
demonstrated that Zscan4c plays a role in maintaining ESC pluripotency [32], while more recently 
it has been reported that the Zscan4 family plays a key role in telomere elongation and genome 
stability in murine ESCs [34]. These two findings are not incompatible as failure to maintain a 
stable genome would likely result either in differentiation or apoptosis.  
 
Given the fact that PI3Ks have been implicated in regulation of both ESC proliferation and 
pluripotency, we hypothesized that particular isoforms of class IA PI3Ks may couple to distinct 
functional responses in mESCs. siRNA-mediated knock-down or small molecule-based inhibition 
of the p110β PI3K isoform (with TGX-121 or 221) led to a decrease in mESC self-renewal, 
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suggesting p110β couples primarily to maintenance of pluripotency. In contrast, siRNA-induced 
knock-down or inhibition of the p110α catalytic isoform (with PIK-75 or 15e) reduced proliferation, 
without significantly affecting pluripotency [35]. Interestingly, we observed that simultaneous 
inhibition of p110α and p110β reduced self-renewal further, leading us to propose that there may 
be cross-talk between PI3K isoforms in murine ESCs [35]. These observations led us to test 
whether inhibition of other signaling molecules, also implicated in control of the proliferation of 
mouse ESCs, could also potentiate the effects p110β inhibition. We found that sub-optimal doses 
of Rapamycin, used in conjunction with TGX-121, resulted in a greater loss of self-renewal than 
inhibition of p110β alone (Figure 1). Based on our observations it is tempting to propose that 
PI3K signaling plays a role in integrating the signals that maintain pluripotency and those that 
regulate mESC proliferation (for model see Figure 2). Clearly further studies will be required to 
rigorously test this hypothesis.  
 
Glycogen synthase kinase-3 and regulation of ESC fate 
GSK-3 is involved in a wide range of physiological processes including development, proliferation 
and metabolism [36]. In mouse and man two isoforms of GSK-3 exist (α and β) which, although 
highly homologous, play non-redundant roles [37]. Initial reports relating to the role of GSK-3 in 
ESCs were conflicting. Ding et al., reported that a kinase inhibitor, termed TWS119, enhanced 
neuronal differentiation of mouse ES and EC cells [38], the primary target of which was reported 
to be GSK-3β. In contrast, Sato et al., using a chemically distinct GSK-3 inhibitor termed BIO, 
reported that treatment of mouse or human ESCs with BIO enhanced self-renewal and 
pluripotency [39]. This latter report proposed that BIO was acting as a Wnt mimetic, via inhibition 
of GSK-3 and led to the suggestion that Wnt signaling played a role in maintenance of ESC 
pluripotency, a proposal generating much discussion and still not completely resolved [40]. One 
aspect not considered by Sato and co-authors was the fact that GSK-3 can be regulated by many 
different signaling pathways [36]. In particular, in response to growth factor stimulation PI3K 
signalling inactivates GSK-3 via Akt-mediated phosphorylation of Ser9/20 [36]. We sought to 
clarify the role of GSK-3 in ESC self-renewal and used a chemical genetic approach to achieve 
this [41]. Our results demonstrated that in the presence of LIF and serum, inhibition of GSK-3 
activity (with a series of bis-indolylmaleimides) enhanced mouse ESC self-renewal and in 
comparison with BIO and TWS119, our GSK-3 inhibitors showed greater selectivity [41]. 
Interestingly, deletion of all 4 GSK-3 alleles from mouse ESCs cells [42] phenocopied the effect 
of our GSK-3 inhibitors, providing clear evidence that inhibition of GSK-3 enhances mouse ESC 
self-renewal. While our studies were nearing completion, Austin Smith’s team from Cambridge 
described the ‘Ground state’ of mouse ESC pluripotency [40, 43]. Their studies demonstrated that 
pluripotency of mouse ESCs could be maintained in the absence of exogenous growth factors 
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using a minimal medium as long as inhibitors of MEK and GSK-3 were present (‘2i’ conditions). 
Inhibition of MEK signaling blocks the differentiation inducing effects of autonomously secreted 
FGF4 [44, 45], but cells cultured with MEK inhibitors alone grew poorly. Addition of GSK-3 
inhibitors improved clonal propagation and cell growth, leading to the suggestion that GSK-3 
inhibition was required under these very defined conditions to promote cell metabolism and 
proliferation [40, 43], which in turn is consistent with a role for PI3K signaling in controlling mESC 
proliferation. In contrast, we had conducted our studies into GSK-3 action in ESCs in a complete 
medium containing serum and under these conditions inhibition of GSK-3 does not consistently 
alter ESC proliferation (Sanchez-Ripoll and Welham unpublished data). Therefore, it may be that 
the differential roles attributed to GSK-3 in defined versus serum-containing media reflect the 
involvement of GSK-3 in a wide array of cellular responses [36] (see Figure 2) and depending on 
the cellular context, i.e. the composition of the extracellular environment, particular roles take on 
greater importance.  
 
More recently we have exploited our newly developed selective GSK-3 inhibitors to re-evaluate 
the role of GSK-3 in human ESCs. Despite the previous report that BIO can maintain human 
ESCs in a pluripotent state [39], we have found that our GSK-3 inhibitors do just the opposite and 
induce differentiation towards mesendodermal lineages (Bone et al., submitted). These 
observations reflect the findings that treatment of human ESCs with Wnts also promotes 
differentiation [46-48]. Our recent data further highlight the different responses of mouse and 
human ESCs to the same factors. The notion that mouse and human ESCs are derived from 
different developmental stages of embryogenesis has been gaining acceptance within the stem 
cell community and the differential role of GSK-3 signalling that we have demonstrated adds to 
the growing list of differences documented between mouse and human ESCs.  
 
Summary 
It is clear from recent studies that great progress has been made in our understanding of the 
range of molecular signals regulating pluripotency, proliferation and self-renewal of embryonic 
stem cells. The challenge now is to decipher how these pathways are integrated such that 
maintenance of pluripotency and proliferation are coordinately regulated – a challenge that would 
surely benefit from a systems biology approach? 
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Figure 1.  Partial inhibition of mTOR potentiates the loss in self-renewal observed 
upon inhibition of p110β . Murine ESCs were incubated with vehicle (DMSO), LY294002 
or the p110β selective inhibitor TGX-121 at the concentrations indicated in the presence or 
absence of 0.1nM Rapamycin (Rapa). After 4 days colonies were fixed and stained for 
alkaline phosphatase activity. Data shown are represented as the mean percentage of 
alkaline phosphatase positive colonies with S.E.M (n=3). Statistical analysis was conducted 
using AVOVA and Fisher’s post hoc test to compare each treatment, where * indicates 
p<0.05 and ** indicates p<0.01. The number of colonies formed in each condition was not 
significantly different.  
 
Figure 2. Model showing the involvement of PI3K and GSK-3-dependent signals in 
control of mouse ESC behaviour.   The key extracellular, intracellular and nuclear factors 
that regulate mouse ESC proliferation, pluripotency and promotion of differentiation are 
depicted. PI3K isoforms play a role in regulation of both proliferation and maintenance of 
pluripotency, while involvement of GSK-3 signalling in these processes may be dependent 
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